Sirolimus plus palbociclib and fulvestrant for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new form of sirolimus (a targeted drug) combined with palbociclib and fulvestrant for advanced breast cancer that is hormone-sensitive and HER2-negative. It may be an option if you have already tried hormone therapy and it stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your breast cancer is HR-positive and HER2-negative.
- Your cancer has spread to other parts of the body (advanced).
- You have had hormone therapy before and it stopped working, or your cancer came back within 12 months of finishing it.
- You have not had a CDK4/6 inhibitor (like palbociclib) for metastatic cancer.
- You have not had fulvestrant or mTOR inhibitors (like everolimus) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
This study tests a new medicine, PF-08032562, for people with advanced breast or colorectal cancer that has not responded to prior treatments. It aims to see if the drug is safe and can help shrink or slow the cancer.
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
This trial tests a new drug called BMS-986500, alone or with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug is safe and effective.
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
This trial tests a new combination of sirolimus (a targeted therapy) and fulvestrant (a hormone therapy) for people with advanced HR+/HER2- breast cancer whose disease has progressed after prior treatment with a CDK4/6 inhibitor. The goal is to see if the combination can help control the cancer.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.